OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Episode 2 of gastrochat: A Menti B, a Gut Feeling, and a Very Strange Commercial

Where to Take the Best Breaks at ESMO Congress 2026: Coffee, Sweets, and a Little Fun

Meet the Faculty of OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition

Research and Advocacy Opportunity - Pancreatic Cancer Ireland Patient and Family Experience Survey

What’s New On Radiotherapy of Lung Cancer in 2026?

Oncology News, Insights, Stories by OncoDaily

ESMO
Not To Miss

20 Posts Not to Miss from ESMO Congress 2026: Day 1

HERIZON-GEA-01 at esmo 2026
Gastrointestinal Oncology

HERIZON-GEA-01 at ESMO 2026: Updated Overall Survival With Zanidatamab-Based First-Line Treatment in HER2-Positive Gastroesophageal Adenocarcinoma

Sarcoma - OncoDaily
OncoDaily Pulse

OncoDaily Grand Rounds at ESMO 2026: All You Need to Know About Sarcoma

Michelle Mitchell: CRUK Scotland Institute Celebrates 50 Years of Cancer Research and Innovation

UICC Honors Ulrika Årehed Kågström as She Concludes Term as President and 8 Years on Board

Bruce Campbell Cancer Update: What We Know About His Diagnosis, Treatment, and Five-Year Prognosis

Follicular Lymphoma: EHA 2026 Guidelines Move Chemotherapy-Free Combinations to First Relapse

Pavlos Msaouel: Exploring Metastasis-Directed Radiation in the Treatment of SMARCB1-Deficient Renal Medullary Carcinoma?

Research and Advocacy Opportunity - Pancreatic Cancer Ireland Patient and Family Experience Survey

Sunvozertinib (ZEGFROVY) Now Available in the US for Post-Platinum EGFR Exon 20 Insertion NSCLC

Voices
Ruiling Yuan

Ruiling Yuan: Different Meetings, Same Passion for Oncology, Leadership, and Advocacy!

Joanna Metzner-Sadurski: Improving Clinical Trial Access Through Health Literacy and Patient Support

Erika Hamilton Shares PANKU-Breast01 Phase III Results in Metastatic Breast Cancer

Jason A. Mouabbi: Can Reflex Liquid NGS Add to Tissue NGS and Tumor-Informed ctDNA Monitoring?

Florian Scotté: New Strategic Partnership Between League Against Cancer and AFSOS

Amol Akhade: First RCT for Personalized mRNA Vaccine in Cancer Patients

Marco Donia: What Should We Watch in Solid-Tumour Cell Therapy at ESMO 2026?

FDA Approvals
CLL/SLL Pirtobrutinib

FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Niklas Klümper: FDA Approves Belzutifan Plus Lenvatinib in Advanced ccRCC

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Floretyrosine F 18 for PET Imaging in Glioma

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

Celebrities and Cancer

OncoCalendar

OncoDaily – Who Owns the Message Brunch during ESMO 2026

OncoDaily

24 Oct
ESMO 2026

OncoDaily – Big Questions During ESMO 2026

OncoDaily

24 Oct
Big Questions During ESMO 2026

OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition

OncoDaily

25 Oct
Bladder Cancer Edition

SITC Computational Immuno-Oncology – Systems Immunology

Society for Immunotherapy of Cancer

27 Oct
TCR-Antigen Binding

2026 NCODA International Fall Summit

NCODA

28 Oct
NCODA International Fall Summit

Advancing Surgical Oncology in the Era of Multidisciplinary Cancer Care

Memorial Sloan Kettering Cancer Center (MSK)

28 Oct
Advancing Surgical Oncology

SPCC Webinar: Integrative Oncology from Biological Mechanisms to Clinical Impact

Sharing Progress in Cancer Care (SPCC)

28 Oct
SPCC

ESOI Touchdown 2026

European Society of Oncologic Imaging

29 Oct
ESOI Touchdown 2026

2026 IBRI Global Forum on Science, Philanthropy, and Investment

Indiana Biosciences Research Institute (IBRI)

29 Oct
IBRI Global forum

The IBRI Global Forum

Indiana Biosciences Research Institute (IBRI)

29 Oct
IBRI Global Forum

ESO Ambassador Event on Neoadjuvant and Post-Neoadjuvant Treatment in Breast Cancer

European School of Oncology (ESO) College

30 Oct
Breast Cancer

2026 Advances in Chronic Graft-Versus-Host Disease

Memorial Sloan Kettering Cancer Center (MSK)

30 Oct
Graft-Versus-Host Disease

Immune-oncology
HBI-8000-303 Trial: Can HDAC Inhibition Improve Immunotherapy in Advanced Melanoma?

HBI-8000-303 Trial: Can HDAC Inhibition Improve Immunotherapy in Advanced Melanoma?

STARBOARD Trial: Rethinking First-Line Therapy in BRAF-Mutant Melanoma

neoHIP Trial: Biomarker-Guided Immunotherapy in HER2-Positive Breast Cancer

KEYNOTE-B15/EV-304: Can ctDNA Predict Outcomes in MIBC?

AMPLIFY-7P Trial: Targeting KRAS With Immunotherapy in Resected Pancreatic Cancer

CA017-078 Trial: Does Perioperative Nivolumab Add Benefit in MIBC?

Pembrolizumab: What Determines Response to PD-1 Blockade?

Gastrointestinal-Oncology
KC-WISE at ESMO 2026

KC-WISE at ESMO 2026: Updated Overall Survival With Anbenitamab Plus Chemotherapy in HER2-Positive Gastric and GEJ Cancer

FORTITUDE-101 and FORTITUDE-102 at ESMO 2026: Bemarituzumab Efficacy by FGFR2 Amplification Status in Gastric and GEJ Cancer

RAMIRIS Trial at ESMO 2026: FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab in Advanced Gastroesophageal Adenocarcinoma

HERIZON-GEA-01 at ESMO 2026: Updated Overall Survival With Zanidatamab-Based First-Line Treatment in HER2-Positive Gastroesophageal Adenocarcinoma

RASolute 302 at ESMO 2026: Daraxonrasib Versus Chemotherapy in Metastatic Pancreatic Cancer – Additional Subgroup Analyses

11 Colorectal Cancer Trials to Watch at ESMO 2026

ESMO 2026 Guideline: Key Updates in Gastric and Esophageal Cancer Management

Breast-Oncology
NATALEE

NATALEE: Ribociclib Delivers Overall Survival Benefit at 6 Years in HR+/HER2− Early Breast Cancer

TALENT Final Results: Neoadjuvant T-DXd Shows Modest Pathologic Activity in HR+/HER2-Low Early Breast Cancer

APEX-Breast01: TQB2102 Cuts Progression Risk by 71% in HER2-Low Advanced Breast Cancer

DESTINY-Breast05: T-DXd Preserves Quality of Life While Improving Outcomes in HER2+ Early Breast Cancer

PANKU-Breast01: Izalontamab Brengitecan Reduces Progression Risk by 59% in HR+/HER2− Advanced Breast Cancer

HORIZON-Breast06: Trastuzumab Rezetecan Reduces Progression Risk by 73% in HER2-Low Advanced Breast Cancer

PATINA: Major FDA–EMA Divide Over Palbociclib in HER2+ Breast Cancer

Lung-Oncology
ZEGFROVY

Sunvozertinib (ZEGFROVY) Now Available in the US for Post-Platinum EGFR Exon 20 Insertion NSCLC

KRAS Mutant NSCLC in 2026: From G12C Inhibition to RAS(ON), Pan-RAS and Combination Strategies

RASolve 308: Phase III Trial Tests Zoldonrasib With Pembrolizumab and Chemotherapy in First-Line RAS G12D NSCLC

Oncogene-Driven NSCLC in 2026: Targeted Therapy Expands Across Mutations, Resistance and CNS Disease

ESMO 2026: 10 ADCs in Lung Cancer to Watch

FURTHER: Firmonertinib Shows Promising Activity in EGFR PACC-Mutant Advanced NSCLC

LIGHT-NING: Real-World Nivolumab Plus Ipilimumab Shows Durable Outcomes in Metastatic NSCLC

OncoDaily TV
Dr Gevorg Tamamyan

Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg Tamamyan’s WHO DG Campaign

Rachel Purcell

Rachel Purcell Highlights New Zealand’s Nationwide Exercise Program for Bowel Cancer Patients

Alicia Fong

Alicia Fong: Exploring the Role of AI in Cancer Detection and Treatment

Dr Gevorg Tamamyan

“Stronger Regions, Stronger Countries…” – Dr Gevorg Tamamyan

Rejin Kebudi

“Diligent, Intelligent, Capable of Reaching Many Colleagues Globally ” – Rejin Kebudi, General Secretary of the International Society of Pediatric Oncology, about Dr Gevorg Tamamyan Upon His WHO DG Candidacy

Dr. Gevorg Tamamyan

“One of the Most Amazing and Truly Legendary Oncologists of Our Time” – Dr. Gevorg Tamamyan on Dr. Julie Gralow, Chief Medical Officer of ASCO

Dr Gevorg Tamamyan

“I Still Remember His Mentees That Spoke So Highly of Him… Having a Vision Means Investing in People That Will Make a Difference For the Years to Come” – Albanian Hematologist Liri Seraj Supports Dr Gevorg Tamamyan as WHO DG Candidate

World Radiotherapy Awareness Day

12 Countries, One Vision for the Future of Radiotherapy – World Radiotherapy Awareness Day

Bishal Gyawali

Erika Ruiz-Garcia Joins Bishal Gyawali on Grounded In Groundshot Podcast

Dr Gevorg Tamamyan

“One Planet is Not Enough For His Vision” – Dr Amalya Sargsyan Celebrates Her Mentor Dr Gevorg Tamamyan

Dr Gevorg Tamamyan

Renowned Surgeon and Inventor of Abraxane, Philanthropist Dr Patrick Soon-Shiong Endorses Dr Gevorg Tamamyan as WHO Director-General Candidate

Burnout

Oncology Beyond Guidelines: Burnout, Imposter Syndrome, Mentorship & Cancer Prevention with Imène Hadji

Not To Miss
ESMO

20 Posts Not to Miss from ESMO Congress 2026: Day 1

UICC Announces New Board of Directors for 2026–2028

Zainab Shinkafi-Bagudu Assumes the Role of UICC President

C. S. Pramesh Has Been Elected UICC President-Elect for the 2026–2028 Term

Revolution Medicines Begins Phase 3 RASolve 308 Trial of Zoldonrasib in RAS G12D Non-squamous NSCLC

ESMO Congress 2028 Heads to Milan: An International Gathering for Cancer Research and Care

20 Posts Not To Miss From ASCOQLTY26

OncoGrants
Allied World–St. Baldrick’s Survivorship

Allied World–St. Baldrick’s Survivorship and Supportive Care Research Grant 2027

Israel Cancer Research Fund

Israel Cancer Research Fund — Career Development Awards 2027–2028

CRI

CRI Lloyd J. Old STAR Program 2027

Graduate Hematology Award

ASH Graduate Hematology Award 2027

John Robert Lewis

AACR-Lustgarten Foundation Career Development Award for Pancreatic Cancer Research - in Honor of John Robert Lewis 2027

Biology to Prevention

American Cancer Society–Cancer Research UK Biology to Prevention Award 2026

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions

CancerWorld

Oncologists
Leo Mascarenhas

Leo Mascarenhas

Oncologists Location Los Angeles, USA
Cristina Smolenschi

Cristina Smolenschi

Oncologists Location Villejuif, France
Jasmine Kamboj

Jasmine Kamboj

Oncologists Location Red Wing, USA
Enrique Soto Perez de Celis

Enrique Soto Pérez de Celis

Oncologists Location Aurora, USA
Melvin L.K. Chua

Melvin L.K. Chua

Oncologists Location Singapore, Singapore
Dickran Kazandjian

Dickran Kazandjian

Oncologists Location Miami, USA
Tetiana Shevchuk

Tetiana Shevchuk

Oncologists Location Kyiv, Ukraine
Kathleen Schmeler

Kathleen Schmeler

Oncologists Location Houston, USA

Drugs Atlas
Fedratinib (Inrebic): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Myelofibrosis Fedratinib (Inrebic) Oct 23, 2026 2:28 am
Ponatinib (Iclusig): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in CML and Philadelphia Chromosome-Positive ALL Ponatinib (Iclusig) Oct 23, 2026 2:03 am
Bosutinib (Bosulif): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Chronic Myeloid Leukemia Bosutinib (Bosulif) Oct 22, 2026 1:37 am
Nilotinib: Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Chronic Myeloid Leukemia Nilotinib Oct 22, 2026 1:35 am
Dasatinib (Sprycel): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in CML and Philadelphia Chromosome-Positive ALL Dasatinib (Sprycel) Oct 21, 2026 1:37 am
Imatinib (Gleevec): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in CML, GIST, and Other KIT/PDGFR-Driven Malignancies Imatinib (Gleevec) Oct 20, 2026 1:36 am
Lenvatinib (Lenvima): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Thyroid Cancer, RCC, HCC, and Endometrial Cancer Lenvatinib (Lenvima) Oct 18, 2026 2:06 pm
Regorafenib (Stivarga): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Colorectal Cancer, GIST, and Hepatocellular Carcinoma Regorafenib (Stivarga) Oct 18, 2026 2:05 pm
Sorafenib (Nexavar): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in HCC, RCC, and Differentiated Thyroid Cancer Sorafenib (Nexavar) Oct 18, 2026 2:14 am
Pazopanib: Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Renal Cell Carcinoma and Soft Tissue Sarcoma Pazopanib Oct 18, 2026 2:13 am

OncoDaily Magazine

New Paper Alert
Jennifer Bailey-Lundberg

Jennifer Bailey-Lundberg: New Findings on Tumor Immune Remodeling in PDAC

Vinidh Paleri

Vinidh Paleri: Study of Over 30,000 Patients Identifies Key Drivers of Head and Neck Cancer Treatment Delays

Drew Moghanaki

Drew Moghanaki: SBRT as a Non-Surgical Alternative for Pulmonary Nodules

One Biosciences

Uncovering Hidden Drivers of Chemotherapy Resistance in Ovarian Cancer - One Biosciences

Stephen Liu

Stephen Liu on the AMAZE-lung Trial of Amivantamab, Lazertinib, and Bevacizumab in EGFR-Mutant NSCLC

Michael Dickinson,

Michael Dickinson Highlights Outcomes and CNS Relapse Patterns in High-Grade B-Cell Lymphoma

OncoDaily Medical Journal

Breast Cancer

10.69690/ODMJ-001-1026-8231

Variable-Volume Oncoplastic Reconstruction Using a Modified Würinger Central Pedicle Technique for Upper Quadrants Breast Cancer: a single-center experience
Original Research

GI Oncology

10.69690/ODMJ-001-1026-8138

Association of Alpha-Fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Camrelizumab Plus Rivoceranib vs Sorafenib: Post Hoc Exploratory Analysis of the CARES-310 Trial
Original Research

Oncology Nursing

10.69690/ODMJ-002-0926-8087

Risk of Atrial Fibrillation in Breast Cancer Patients Treated with Radiotherapy: A Scoping Review
Reviews

Pediatric Oncology

10.69690/ODMJ-011-0826-7849

Integrated Management of Endo and Exo-pelvic Sacrococcygeal Teratomas (Altman type III): Report of Two Cases
Case Reports & Case Series

Oncology Nursing

10.69690/ODMJ-001-0826-7778

Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Original Research

Oncology Nursing

10.69690/ODMJ-002-0826-7795

Late presentation in cancer care: Implications for treatment and survival: A Narrative Review
Reviews

GI Oncology

10.69690/ODMJ-018-0826-7959

From Plate to Polyps: Dietary N-Nitrosamines and Biomarkers of DNA Damage
Abstracts

Head and Neck Cancer

10.69690/ODMJ-018-0826-7933

A Service Review of PD-L1 Biomarker Use in the Head and Neck Cancer Service
Abstracts